Amgen Rivals Teva With Rituximab Approved For RA
US Market Composed Of Three Biosimilars Plus Rituxan
Amgen has added a further treatment for inflammatory diseases to its vast portfolio, with the FDA approving its rituximab biosimilar Riabni for rheumatoid arthritis.
You may also be interested in...
A balanced policy environment that can support biosimilar competition is needed to allow the drugs to flourish in the US, says Amgen’s executive director of marketing and global biosimilars commercial lead Chad Pettit.
Amgen expects a significant shift in the US biosimilars landscape as Humira rivals launch next year, Chad Pettit, the firm’s executive director of marketing and global biosimilars lead, tells Generics Bulletin. The company expects to be first to market with its version of adalimumab from the end of January 2023, helping to drive long-term growth ambitions for its biosimilars business.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker